시장보고서
상품코드
1266586

세계의 세포 기반 어세이 시장 - 세계 및 지역별 분석 : 제품별, 서비스별, 용도별, 최종사용자별, 기술별, 지역별 분석, 경쟁 상황 - 분석과 예측(2023-2032년)

Global Cell-Based Assay Market - A Global and Regional Analysis: Focus on Product, Services, Application, End User, Technology, Regional Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2032

발행일: | 리서치사: BIS Research | 페이지 정보: 영문 | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포 기반 어세이 시장 규모는 예측기간 2023-2032년에 CAGR로 8.44%의 성장이 전망되며, 2022년 172억 달러에서 2032년에는 382억 3,000만 달러로 확대될 것으로 예측됩니다.

세계의 세포 기반 어세이 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 서비스별, 용도별, 최종사용자별, 기술별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 정의

제2장 조사 범위

제3장 조사 방법

제4장 시장 개요

  • 시장 서론

제5장 업계 인사이트

  • 개요
  • 미국의 법적 요건과 체계
  • 유럽의 법적 요건과 체계
  • 아시아태평양의 법적 요건과 체계

제6장 시장 역학

  • 개요
  • 영향 분석
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회

제7장 경쟁 상황

  • 경쟁 상황 개요
  • 시장 점유율 분석(2022년)
  • 성장 점유율 분석(2021-2022년)

제8장 세계의 세포 기반 어세이 시장(제품별), 10억 달러, 2022-2032년

  • 개요
  • 소모품
    • 시약
    • 어세이 키트
    • 마이크로플레이트
    • 세포주
    • 프로브와 라벨
    • 기타 소모품
  • 계측기와 소프트웨어
  • 서비스

제9장 세계의 세포 기반 어세이 시장(용도별), 10억 달러, 2022-2032년

  • 개요
    • 약물 스크리닝
    • 기초 연구
    • 예측 독성학
    • 기타

제10장 세계의 세포 기반 어세이 시장(최종사용자별), 10억 달러, 2022-2032년

  • 개요
  • 제약회사 및 바이오의약품 기업
  • CRO
  • 학술연구기관
  • 기타

제11장 세계의 세포 기반 어세이 시장(기술별), 10억 달러, 2022-2032년

  • 개요
  • 유세포 분석
  • 자동 처리
  • High Throughput Screening
  • High Content Screening
  • 기타

제12장 세계의 세포 기반 어세이 시장(지역별), 10억 달러, 2022-2032년

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 기타 지역

제13장 기업 개요

KSM 23.05.08

“Global Cell-Based Assay Market to Reach $38.23 Billion by 2032.”

Industry Overview

The global cell-based assay market is expected to reach $38.23 billion in 2032 from $17.20 billion in 2022, at a CAGR of 8.44% during the forecast period 2023-2032.

Market Lifecycle Stage

The global cell-based assay market is anticipated to witness growth during the forecast year 2023-2032, largely fuelled by the promise of a novel breakthrough in the cell-based assay market, which is no longer restricted to drug discovery. The foremost advantage of utilizing cell-based assays is apparent: unlike basic biochemical assays, they provide a more comprehensive representation of biological systems as they encompass not just an isolated receptor or enzyme but all the organelles of a cell functioning as a single entity.

Impact

The impact analysis for the factors that significantly affect the market, namely, drivers, restraints, and opportunities, has been evaluated on a short-term and long-term basis. The short-term assessment considers the period between 2022 and 2026, and the long-term assessment considers the period between 2027 and 2032. Key developments and strategies that have been undertaken by some of the key players in this market have been accounted for evaluation of the impact analysis. Further, these key developments have been assessed to understand the future scope of integrating advancing technologies to enable superior outcomes.

Impact of COVID-19

The cell-based assay market has also been impacted by the pandemic. As per World Health Organization (WHO), COVID-19 has affected millions of people, resulting in a considerable number of deaths. In response, companies have intensified their research and development efforts to create vaccines and treatments for the SARS-CoV-2 virus. This research is considered critical and has remained unaffected, with operations and output continuing as before. As a result of the increase in research activities, the availability of research funding and demand for cell-based test products are expected to expand.

Companies in the industry are adapting their long-and short-term growth strategies to capitalize on opportunities in the research market by introducing innovative products to combat the pandemic. The need for COVID-19 research has created a broad scope for cell-based tests in viral infection research, vaccine development, and drug discovery.

Various COVID-19 vaccines and antiviral medications have been authorized or are under development, and patients are being treated symptomatically. The functional efficiency of the antibodies produced to neutralize the virus is assessed using cell-based assays for both vaccines and treatments. In order to reduce time and increase throughput, cell-based assays are utilized. As a result, the demand for cell-based assays to provide early indications of symptoms in patients has increased. Consequently, the overall impact of COVID-19 on the cell-based assay market is predicted to be positive.

Market Segmentation:

Global Cell-Based Assay Market

Segmentation 1: by Product

  • Consumables
  • Instruments and Software
  • Services

Based on product type, the global cell-based assay market is segmented into consumables, instruments and software, and services.

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

In 2022, the North America region dominated the global cell-based assay market, and it is expected to hold its dominance throughout the forecast period 2023-2032.

Segmentation 3: by Application

  • Drug Screening
  • Basic Research
  • Predictive Toxicology
  • Other Applications (Other Industries, Cell and Gene therapy, among others)

As of 2022, the cell-based assay market (by application) was dominated by drug screening applications, holding a 41.27% market share.

Segmentation 4: by Technology

  • Flow Cytometry
  • Automated Handling
  • High Throughput Screening
  • High Content Screening
  • Other Technologies (Label-Free Detection, Image Cytometry, among others)

As of 2022, the global cell-based assay market (by technology) was dominated by flow cytometry, holding a 34.11% market share.

Segmentation 5: by End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Other End Users (Government Organizations)

As of 2022, the global cell-based assay market (by end user) was dominated by the pharmaceutical and biopharmaceutical companies' segment, holding a 51.36% market share.

Segmentation 6: by Company

  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Corning Incorporated
  • Lonza Group AG
  • Agilent Technologies, Inc.
  • Promega Corporation
  • PerkinElmer, Inc.
  • Eurofins DiscoverX Products
  • Cell Signaling Technology, Inc.
  • Charles River Laboratories International, Inc.
  • Laboratory Corporation of America Holdings

Based on company, the global cell-based assay market is dominated by Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, among others.

Recent Developments in the Global Cell-Based Assay Market

  • In April 2022, Lonza Group AG announced an enhancement to its automated cell therapy manufacturing system called the Cocoon Platform. The latest addition, known as magnetic selection, broadens the platform's capabilities by enabling cell binding, separation, and bead removal (if needed), all conducted through the Cocoon cassette.
  • In April 2020, Bio-Rad Laboratories, Inc. completed the acquisition of Celsee, Inc., a company that provides instruments and consumables that enable the isolation, detection, and analysis of individual cells.
  • In July 2021, PerkinElmer, Inc. announced that it had reached a definitive agreement to acquire BioLegend, a manufacturer of high-quality antibodies and reagents used in biomedical research, for $5.25 billion.
  • In April 2021, Lonza Group AG and Junshi Biosciences announced an expansion of their collaboration aimed at developing and manufacturing biologics. Lonza Group AG would utilize its worldwide network and local operational expertise to help Junshi Biosciences speed up the development of drugs in its pipeline and increase their adoption in the global market. According to the agreement, Lonza Group AG would provide comprehensive assistance, including cell line creation and development, the supply of cell culture media and reagents, process development, and GMP manufacturing.
  • In July 2021, Lonza Group AG and CN Bio established a distribution agreement that involves Lonza Group AG providing hepatic cells to CN Bio for prequalification, which would be utilized in their PhysioMimix single-and multi-organ MPS technology. This collaboration aims to revolutionize the generation of preclinical data that is relevant to humans. By using prequalified cells, customers can avoid the need to experiment with multiple cell types, thereby saving time and ensuring the discovery of cells that will grow and function effectively in 3D culture.

Demand - Drivers and Limitations

The following are the demand drivers for the global cell-based assay market:

  • Increase in Demand for Cell-Based Assay in Drug Discovery and Development
  • Rise in Life Sciences Research Investments
  • Technological Advancements

The market is expected to face some limitations due to the following challenges:

  • High Cost
  • Lack of Standardization

How can this report add value to an organization?

Workflow/Innovation Strategy: The global cell-based assay market is segmented (by product) into three categories, i.e., consumables, instruments and software, and services. The consumables segment is further classified as reagents, assay kits, microplates, cell lines, probes and labels, and other consumables.

Reagents accounted for 29.43% of the share in the global cell-based assay market from 2022 to 2032.

Growth/Marketing Strategy: The global cell-based assay market is anticipated to witness growth during the forecast year 2023-2032. The advent of CRISPR/Cas9 technology has completely transformed gene studies and their functions by offering highly precise and user-friendly genome editing capabilities. CRISPR significantly streamlines the development of more intricate disease-related cell-based assays, enabling researchers to tackle complex questions and study heterogeneous diseases with more relevant and sophisticated assays.

Competitive Strategy: Key players in the global cell-based assay market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell-based assay market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

1 Definition

  • 1.1 Inclusion and Exclusion Criteria

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report:

3 Research Methodology

  • 3.1 Global Cell-Based Assay Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Markets Overview

  • 4.1 Market Introduction
    • 4.1.1 Types of Cell-Based Assays
  • 4.2 Current and Future State of Cell-Based Assays in Industries
  • 4.3 Emerging Technologies and Applications in the Global Cell-Based Assay Market
  • 4.4 Current Market Size and Growth Potential, $Billion, 2022-2032
  • 4.5 COVID-19 Impact on Global Cell-Based Assay Market
    • 4.5.1 Impact on Cell-Based Assay Companies

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Frameworks in the U.S.
  • 5.3 Legal Requirements and Frameworks in Europe
  • 5.4 Legal Requirements and Frameworks in Asia-Pacific
    • 5.4.1 Legal Requirements and Frameworks in Japan

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
    • 6.2.1 Market Drivers
      • 6.2.1.1 Increase in Demand for Cell-Based Assay in Drug Discovery and Development
      • 6.2.1.2 Rise in Life Sciences Research Investments
      • 6.2.1.3 Technological Advancements
    • 6.2.2 Market Restraints
      • 6.2.2.1 High Cost
      • 6.2.2.2 Lack of Standardization
    • 6.2.3 Market Opportunities
      • 6.2.3.1 Increased Focus on Regenerative Medicine
      • 6.2.3.2 Emergence of Novel Gene Editing Technologies

7 Competitive Landscape

  • 7.1 Competitive Landscape Overview
    • 7.1.1 Key Developments
    • 7.1.2 Product Launch and Expansion Activities
    • 7.1.3 Merger and Acquisition Activities
    • 7.1.4 Synergistic Activities
    • 7.1.5 License and Agreement Activities
  • 7.2 Market Share Analysis (2022)
  • 7.3 Growth-Share Analysis (2021-2022)
    • 7.3.1 Growth-Share Analysis (by Company)

8 Global Cell-Based Assay Market (by Product),$Billion, 2022-2032

  • 8.1 Overview
  • 8.2 Consumables
    • 8.2.1 Reagents
    • 8.2.2 Assay Kits
    • 8.2.3 Microplates
    • 8.2.4 Cell Lines
    • 8.2.5 Probes and Labels
    • 8.2.6 Other Consumables
  • 8.3 Instruments and Software
  • 8.4 Services

9 Global Cell-Based Assay Market (by Application), $Billion, 2022-2032

  • 9.1 Overview
    • 9.1.1 Drug Screening
    • 9.1.2 Basic Research
    • 9.1.3 Predictive Toxicology
    • 9.1.4 Other Applications (Other Industries, Cell and Gene Therapy, and Others)

10 Global Cell-Based Assay Market (by End User), $Billion, 2022-2032

  • 10.1 Overview
  • 10.2 Pharmaceutical and Biopharmaceutical Companies
  • 10.3 Contract Research Organizations (CROs)
  • 10.4 Academic and Research Institutes
  • 10.5 Other End Users (Government Organizations)

11 Global Cell-Based Assay Market (by Technology), $Billion, 2022-2032

  • 11.1 Overview
  • 11.2 Flow Cytometry
  • 11.3 Automated Handling
  • 11.4 High-Throughput Screening
  • 11.5 High-Content Screening
  • 11.6 Other Technologies (Label-Free Detection, Image Cytometry, and Others)

12 Global Cell-Based Assay Market (by Region), $Billion, 2022-2032

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 U.K.
    • 12.3.3 France
    • 12.3.4 Italy
    • 12.3.5 Spain
    • 12.3.6 Rest-of-Europe
  • 12.4 Asia-Pacific
    • 12.4.1 China
    • 12.4.2 Japan
    • 12.4.3 India
    • 12.4.4 South Korea
    • 12.4.5 Australia
    • 12.4.6 Rest-of-Asia-Pacific
  • 12.5 Rest-of-the-World

13 Company Profiles

  • 13.1 Overview
    • 13.1.1 Becton, Dickinson and Company
      • 13.1.1.1 Company Overview
      • 13.1.1.2 Role of Becton, Dickinson and Company in the Global Cell-Based Assay Market
      • 13.1.1.3 Major Product: Key Specifications
      • 13.1.1.4 Customers and Competitions
        • 13.1.1.4.1 Key Customers
        • 13.1.1.4.2 Key Competitors
      • 13.1.1.5 Analyst Perspective
    • 13.1.2 Bio-Rad Laboratories, Inc.
      • 13.1.2.1 Company Overview
      • 13.1.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Cell-Based Assay Market
      • 13.1.2.3 Major Product: Key Specifications
      • 13.1.2.4 Customers and Competitions
        • 13.1.2.4.1 Key Customers
        • 13.1.2.4.2 Key Competitors
      • 13.1.2.5 Analyst Perspective
    • 13.1.3 Danaher Corporation
      • 13.1.3.1 Company Overview
      • 13.1.3.2 Role of Danaher Corporation in the Global Cell-Based Assay Market
      • 13.1.3.3 Major Product: Key Specifications
      • 13.1.3.4 Customers and Competitions
        • 13.1.3.4.1 Key Customers
        • 13.1.3.4.2 Key Competitors
      • 13.1.3.5 Analyst Perspective
    • 13.1.4 Merck KGaA
      • 13.1.4.1 Company Overview
      • 13.1.4.2 Role of Merck KGaA in the Global Cell-Based Assay Market
      • 13.1.4.3 Major Product: Key Specifications
      • 13.1.4.4 Key Competitors
      • 13.1.4.5 Analyst Perspective
    • 13.1.5 Thermo Fisher Scientific, Inc.
      • 13.1.5.1 Company Overview
      • 13.1.5.2 Role of Thermo Fisher Scientific, Inc. in the Global Cell-Based Assay Market
      • 13.1.5.3 Major Product: Key Specifications
      • 13.1.5.4 Key Competitors
      • 13.1.5.5 Analyst Perspective
    • 13.1.6 Corning Incorporated
      • 13.1.6.1 Company Overview
      • 13.1.6.2 Role of Corning Incorporated in the Global Cell-Based Assay Market
      • 13.1.6.3 Major Product: Key Specifications
      • 13.1.6.4 Key Competitors
      • 13.1.6.5 Analyst Perspective
    • 13.1.7 Lonza Group AG
      • 13.1.7.1 Company Overview
      • 13.1.7.2 Role of Lonza Group AG in the Global Cell-Based Assay Market
      • 13.1.7.3 Major Product: Key Specifications
      • 13.1.7.4 Key Competitors
      • 13.1.7.5 Analyst Perspective
    • 13.1.8 Agilent Technologies, Inc.
      • 13.1.8.1 Company Overview
      • 13.1.8.2 Role of Agilent Technologies, Inc. in the Global Cell-Based Assay Market
      • 13.1.8.3 Major Product: Key Specifications
      • 13.1.8.4 Customers and Competitions
        • 13.1.8.4.1 Key Customers
        • 13.1.8.4.2 Key Competitors
      • 13.1.8.5 Analyst Perspective
    • 13.1.9 Promega Corporation
      • 13.1.9.1 Company Overview
      • 13.1.9.2 Role of Promega Corporation in the Global Cell-Based Assay Market
      • 13.1.9.3 Major Product: Key Specifications
      • 13.1.9.4 Customers and Competitions
        • 13.1.9.4.1 Key Customers
        • 13.1.9.4.2 Key Competitors
      • 13.1.9.5 Analyst Perspective
    • 13.1.10 PerkinElmer, Inc.
      • 13.1.10.1 Company Overview
      • 13.1.10.2 Role of PerkinElmer Inc. in the Global Cell-Based Assay Market
      • 13.1.10.3 Major Product: Key Specifications
      • 13.1.10.4 Key Competitors
      • 13.1.10.5 Analyst Perspective
    • 13.1.11 Eurofins DiscoverX Products
      • 13.1.11.1 Company Overview
      • 13.1.11.2 Role of Eurofins DiscoverX Products in the Global Cell-Based Assay Market
      • 13.1.11.3 Major Product: Key Specifications
      • 13.1.11.4 Key Competitors
      • 13.1.11.5 Analyst Perspective
    • 13.1.12 Cell Signaling Technology, Inc.
      • 13.1.12.1 Company Overview
      • 13.1.12.2 Role of Cell Signaling Technology, Inc. in the Global Cell-Based Assay Market
      • 13.1.12.3 Major Product: Key Specifications
      • 13.1.12.4 Key Competitors
      • 13.1.12.5 Analyst Perspective
    • 13.1.13 Charles River Laboratories International, Inc.
      • 13.1.13.1 Company Overview
      • 13.1.13.2 Role of Charles River Laboratories International, Inc. in the Global Cell-Based Assay Market
      • 13.1.13.3 Major Product: Key Specifications
      • 13.1.13.4 Key Competitors
      • 13.1.13.5 Analyst Perspective
    • 13.1.14 Laboratory Corporation of America Holdings
      • 13.1.14.1 Company Overview
      • 13.1.14.2 Role of Laboratory Corporation of America Holdings in Global Cell-Based Assay Market
      • 13.1.14.3 Major Product: Key Specifications
      • 13.1.14.4 Key Competitors
      • 13.1.14.5 Analyst's Perspective
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제